Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Nicholas Morrell | M | 62 |
Morphogen-IX Ltd.
 Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | 9 Jahre |
| David Grainger | M | 58 |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | 9 Jahre |
| Kevin Johnson | M | 64 |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Anne Dobree | M | - |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Robert Tansley | M | 61 |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Anton Noordegraaf | M | - |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Martin Wilkins | M | - |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Mark Toshner | M | - |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigtes Königreich | 8 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Marc Humbert
- Persönliches Netzwerk
